KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Q4 2025 value amounting to $6.5 million.

  • Vertex Pharmaceuticals' Other Non Operating Income rose 14362.42% to $6.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.7 million, marking a year-over-year increase of 9105.69%. This contributed to the annual value of -$7.7 million for FY2025, which is 9105.69% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Other Non Operating Income of $6.5 million as of Q4 2025, which was up 14362.42% from -$9.8 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Other Non Operating Income high stood at $42.4 million for Q3 2021, and its period low was -$78.1 million during Q2 2022.
  • For the 5-year period, Vertex Pharmaceuticals' Other Non Operating Income averaged around -$13.8 million, with its median value being -$12.4 million (2023).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 250000.0% in 2024, then skyrocketed by 15714.29% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Other Non Operating Income stood at $7.1 million in 2021, then plummeted by 538.03% to -$31.1 million in 2022, then skyrocketed by 68.49% to -$9.8 million in 2023, then tumbled by 52.04% to -$14.9 million in 2024, then soared by 143.62% to $6.5 million in 2025.
  • Its Other Non Operating Income stands at $6.5 million for Q4 2025, versus -$9.8 million for Q3 2025 and $13.2 million for Q2 2025.